- Khiron partners with Nimbus Health, a leading medical cannabis
distributor in Germany, with broad
reach into domestic pharmacies
- First import and sales of Khiron branded EU GMP medical
cannabis products are expected in Q3/20
- Medical education and marketing activities to begin
imminently
- Germany is the largest medical
cannabis market in Europe with
€123M of fully reimbursed patient prescriptions in 2019 (source:
GKV)
- By 2028, the German medical cannabis market is predicted to be
worth nearly €7.7bn (source: Prohibition Partners)
TORONTO, June 25, 2020 /CNW/ - Khiron Life Sciences
Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF),
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America and Europe, announces that it has entered into an
agreement with Nimbus Health, a leading German distributor of
medical cannabis products. Khiron branded EU GMP medical
cannabis will soon be available in Germany for prescription by doctors and
dispensation in pharmacies.
Tejinder Virk, President of
Khiron Europe, commented: "This is a major milestone for our
company. Following our recent entry into the United Kingdom, the expansion into
Germany will greatly benefit
patients who still suffer from inconsistent supply. Khiron is
now well positioned to service this rapidly expanding market in
Germany."
The supply of EU GMP medical cannabis to Germany will be fully supported by the
Company's global medical education team, led by Dr. Maria Fernanda Arboleda, Khiron's International
Director for Medical Services. Dr. Arboleda is an Anesthesiologist,
Pain and Palliative Care Physician. She completed a Spine-Regional
Anesthesia Fellowship at the McGill
University Health Center and a Post-Doctoral Research Fellow
in Supportive Cancer Care and Medical Cannabis, at the Department
of Oncology, McGill University, and at
Santé Cannabis, a leading specialized cannabis clinic in
Canada.
Franziska Katterbach, Managing Director & Chief Legal
Officer for Khiron Europe based in Frankfurt, commented: "Germany continues to be the European leader in
medical cannabis, with other countries observing and adapting to
the German regulatory model. The market is also differentiated with
its large proportion of patient prescriptions fully reimbursed
through insurance."
About Khiron Life Sciences Corp.
Khiron is a vertically integrated medical and CPG cannabis
company with core operations in Latin
America, and operational activity in Europe and North America. Khiron is
the leading cannabis company in Colombia and the first company licensed
in Colombia for the cultivation, production, domestic
distribution, and international export of both low and high THC
medical cannabis products. The Company has presence in Mexico, Peru,
Uruguay, Brazil, UK and Germany, where it is positioned to begin sales
of medical cannabis.
Leveraging its first-mover advantage, and patient oriented
approach, Khiron combines global scientific expertise, product
innovation, agricultural infrastructure, wholly-owned medical
clinics, and online doctor education programs to drive prescription
and brand loyalty to address priority medical conditions. Its
Wellbeing unit launched the first branded CBD skincare brand in
Colombia, with Kuida now marketed
in multiple jurisdictions in Latin
America, the US and UK. The Company is led by Co-founder and
Chief Executive Officer, Alvaro
Torres, together with an experienced and diverse
executive team and Board of Directors.
Visit Khiron online at www.khiron.ca,
investors.khiron.ca and on Instagram @khironlife
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment analyses,
expectations or statements made by third-parties in respect of
Khiron, its securities, or financial or operating results (as
applicable). Although Khiron believes that the expectations
reflected in forward-looking statements in this press release are
reasonable, such forward-looking statement has been based on
expectations, factors and assumptions concerning future events
which may prove to be inaccurate and are subject to numerous risks
and uncertainties, certain of which are beyond Khiron's control,
including the risk factors discussed in Khiron's Annual Information
Form which is available on Khiron's SEDAR profile at www.sedar.com.
The forward-looking information contained in this press release is
expressly qualified by this cautionary statement and are made as of
the date hereof. Khiron disclaims any intention and has no
obligation or responsibility, except as required by law, to update
or revise any forward-looking information, whether as a result of
new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-signs-distribution-deal-in-germany-for-medical-cannabis-imports-and-sales-301083774.html
SOURCE Khiron Life Sciences Corp.